Comparative Pharmacology
Head-to-head clinical analysis: REDEMPLO versus WEZLANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REDEMPLO versus WEZLANA.
REDEMPLO vs WEZLANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REDEMPLO is a synthetic tricyclic analog that acts as a selective serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It binds to the presynaptic transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT), inhibiting their reuptake and increasing synaptic concentrations of these monoamines. Additionally, it has weak antagonistic properties at the 5-HT2A and alpha-2 adrenergic receptors, contributing to its antidepressant and anxiolytic effects.
WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.
100 mg orally once daily, with or without food.
IV: 500 mg every 12 hours over 60 minutes.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and end-stage renal disease (up to 40 hours).
12 hours (range 10-14 hours); clinically, steady-state is achieved after 2-3 days of dosing.
Primarily hepatic metabolism with 70% renal excretion of metabolites and 30% fecal elimination; less than 5% excreted unchanged in urine.
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal excretion accounts for 20%; the remaining 10% is metabolized.
Category C
Category C
Unknown
Unknown